on site drug screening
play

On-Site Drug Screening An industry perspective IVD Australia Inc - PowerPoint PPT Presentation

On-Site Drug Screening An industry perspective IVD Australia Inc An ASIC registered incorporated company with a board of directors a CEO operating with a constitution & Code of Conduct Industry Peak body representing >50 companies


  1. On-Site Drug Screening An industry perspective

  2. IVD Australia Inc • An ASIC registered incorporated company with a board of directors a CEO operating with a constitution & Code of Conduct • Industry Peak body representing >50 companies • In drug testing market segment companies represented include: Abbott Diagnostics, Alere, MCG Biotech, MP Biomedicals, Perkin Elmer, Randox, Roche Diagnostics, R-Biopharm, Siemens, ThermoFisher • This represents >90% of all on-site drug test kits sold and used in Australia

  3. On-Site Drug Screening a substantial & growing industry segment Industry Aim/Objective • Products and services that enhance and support a safer workplace • Product that is ‘Fit for Purpose’ • Used in field/not a replacement for labs • On-site service providers are not laboratories • Provide world class expertise in drug testing • World best practice with available technologies • Australian requirements needs to be aligned with worldwide requirements

  4. AS4760 – an industry standard • Consultation is key across all sectors • Need appropriate representation on the Committees reflecting all stakeholders – Requires holistic industry representation • The process of creating/changing the Standard needs to be transparent and open • Have achievable outcomes IVD Australia needs to be on the Committees when deciding on the Standard

  5. Issues – Standard/NATA • Development of a clear and workable Standard that supports the users purpose • Accept that there will be compromises required by all parties for achievable outcomes • Accreditation criteria needs to be applied consistently – across all assessors & all sites • Ensure there are no arbitrary decisions made without industry wide consultation

  6. Issues – Standard/NATA (continued) • Product verification – In line with standard manufacturing for lateral flow devices • Availability of viable controls & QAP – Levels suitable for lateral flow devices • Transition period to implement any changes • The Australian market represents approximately 2% of the total worldwide market – Australian requirements needs to be consistent with worldwide requirements

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend